ProMetic Life Sciences Inc. (TSE:PLI)‘s stock had its “speculative buy” rating restated by equities researchers at TD Securities in a research note issued on Wednesday. They presently have a C$4.50 price target on the stock. TD Securities’ target price would indicate a potential upside of 54.11% from the company’s current price.
Several other research firms also recently weighed in on PLI. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of ProMetic Life Sciences in a research note on Thursday, August 25th. Scotiabank reaffirmed an “outperform” rating and set a C$5.00 price target on shares of ProMetic Life Sciences in a research note on Thursday, August 25th. Finally, CIBC decreased their price target on shares of ProMetic Life Sciences from C$5.00 to C$4.85 in a research note on Thursday, August 25th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. ProMetic Life Sciences currently has a consensus rating of “Buy” and an average price target of C$4.84.
Shares of ProMetic Life Sciences (TSE:PLI) opened at 2.92 on Wednesday. ProMetic Life Sciences has a 52 week low of $1.67 and a 52 week high of $3.62. The firm has a 50 day moving average price of $2.88 and a 200 day moving average price of $3.02. The company’s market capitalization is $1.76 billion.
About ProMetic Life Sciences
ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.